Clinically effective antigen-based immunotherapy must silence antigen-experienced effector T cells (Teff) driving ongoing immune pathology. Using CD4(+) autoimmune Teff cells, we demonstrate that peptide immunotherapy (PIT) is strictly dependent upon sustained T cell expression of the co-inhibitory molecule PD-1. We found high levels of 5-hydroxymethylcytosine (5hmC) at the PD-1 (Pdcd1) promoter of non-tolerant T cells. 5hmC was lost in response to PIT, with DNA hypomethylation of the promoter. We identified dynamic changes in expression of the genes encoding the Ten-Eleven-Translocation (TET) proteins that are associated with the oxidative conversion 5-methylcytosine and 5hmC, during cytosine demethylation. We describe a model whereby promoter demethylation requires the co-incident expression of permissive histone modifications at the Pdcd1 promoter together with TET availability. This combination was only seen in tolerant Teff cells following PIT, but not in Teff that transiently express PD-1. Epigenetic changes at the Pdcd1 locus therefore determine the tolerizing potential of TCR-ligation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297948 | PMC |
| http://dx.doi.org/10.7554/eLife.03416 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The miR-23a/27a/24 - 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer.
Mol Cancer
December 2024
Department of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, 400042, China.
Programmed cell death protein ligand-1 (PD-L1) and major histocompatibility complex I (MHC-I) are key molecules related to tumor immune evasion and resistance to programmed cell death protein 1 (PD-1)/PD-L1 blockade. Here, we demonstrated that the upregulation of all miRNAs in the miR-23a/27a/24 - 2 cluster was correlated with poor survival, immune evasion and PD-1/PD-L1 blockade resistance in patients with non-small cell lung cancer (NSCLC). The overexpression of all miRNAs in the miR-23a/27a/24 - 2 cluster upregulated PD-L1 expression by targeting Cbl proto-oncogene B (CBLB) and downregulated MHC-I expression by increasing the level of eukaryotic initiation factor 3B (eIF3B) via the targeting of microphthalmia-associated transcription factor (MITF).
View Article and Find Full Text PDFPD-1 interactome in osteosarcoma: identification of a novel PD-1/AXL interaction conserved between humans and dogs.
Cell Commun Signal
December 2024
International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.
The PD-1/PDL-1 immune checkpoint inhibitors revolutionized cancer treatment, yet osteosarcoma remains a therapeutic challenge. In some types of cancer, PD-1 receptor is not solely expressed by immune cells but also by cancer cells, acting either as a tumor suppressor or promoter. While well-characterized in immune cells, little is known about the role and interactome of the PD-1 pathway in cancer.
View Article and Find Full Text PDFAlternative splicing of PBRM1 mediates resistance to PD-1 blockade therapy in renal cancer.
EMBO J
November 2024
Department of Biochemistry, College of Natural Sciences, Chungnam National University, Daejeon, 34134, Republic of Korea.
Article Synopsis
- Alternative pre-mRNA splicing (AS) contributes to the diversity of proteins but is not well understood in the context of cancer, prompting an analysis of AS in cancer driver genes across fifteen types of cancer.* -
- The study identified significant changes in the inclusion rates of the Polybromo 1 (PBRM1) exon 27 in cancer tissues, which is regulated by the binding of RBFOX2 to specific intronic elements.* -
- It was found that the isoform containing PBRM1 E27 increases PD-L1 expression, and patients with low RBFOX2 levels in clear cell renal cell carcinoma are less responsive to PD-1 therapy, indicating a potential target for treatment strategies.*
Human papillomavirus-encoded circular RNA circE7 promotes immune evasion in head and neck squamous cell carcinoma.
Nat Commun
October 2024
Department of Oral and Maxillofacial Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Article Synopsis
- Immune evasion is a key factor in cancer development and is the basis for tumor immunotherapy, particularly in head and neck squamous cell carcinoma (HNSCC) linked to Human Papillomavirus (HPV).
- The study identifies that HPV-encoded circular RNA, circE7, negatively impacts CD8 T cell infiltration by inhibiting LGALS9 transcription, which is important for T cell function.
- The mechanism involves circE7 binding to ACC1, leading to changes in gene expression that promote T cell suppression, suggesting a potential immunotherapy approach using anti-PD-1 and anti-TIM-3 inhibitors to counteract this immune evasion.
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer.
Cancer Cell
October 2024
Department of Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Institute of Digestive Disease and The Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, CUHK Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China; Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address:
Article Synopsis
- Microsatellite stable (MSS) colorectal cancers (CRCs) usually resist anti-PD-1 therapy, but the presence of the pathogen Fusobacterium nucleatum (Fn) makes these cancers more sensitive to treatment.
- Fecal microbiota transplantation (FMT) from patients with high levels of Fn to germ-free mice enhances anti-PD-1 effectiveness, suggesting a link between Fn and improved treatment response.
- Fn increases butyric acid production in tumors, which helps activate CD8 T cells by altering their function and reduces exhaustion, indicating that Fn may serve as a useful biomarker for predicting responses to anti-PD-1 therapy in MSS CRC patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!